Related Experiment Video
Updated: May 28, 2026
06:25
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
Circulating serologic and molecular biomarkers in malignant melanoma
Shanique R Palmer1, Lori A Erickson, Ilia Ichetovkin
1Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic Proceedings
|October 4, 2011
Summary
Malignant melanoma is a growing public health concern with limited treatment options. Researchers are actively seeking reliable blood biomarkers for early detection and improved patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Biomarker Discovery
Background:
- Malignant melanoma incidence is rising globally, posing a significant public health challenge.
- Advanced melanoma has limited therapeutic options, highlighting the need for better management strategies.
- Current diagnostic and monitoring methods rely on tumor characteristics but melanoma remains unpredictable.
Purpose of the Study:
- To review the current landscape of serologic melanoma biomarkers.
- To understand the reasons behind the failure of previously investigated biomarkers in clinical practice.
- To explore novel approaches in the search for effective melanoma biomarkers.
Main Methods:
- Comprehensive literature review of serologic melanoma biomarkers using the PubMed database.
- Analysis of published investigations on biomarker discovery and validation.
- Synopsis of research efforts and challenges in the field.
Main Results:
- Despite extensive research, a definitive and clinically applicable serologic biomarker for melanoma has not yet been identified.
- Numerous serologic markers have been investigated, but most have not translated into routine clinical use.
- Challenges include lack of specificity, sensitivity, and reproducibility in identified markers.
Conclusions:
- The search for a reliable serologic biomarker for malignant melanoma is ongoing.
- Understanding past research failures is crucial for developing future successful biomarker strategies.
- Innovative methods are being explored to overcome existing limitations in melanoma biomarker discovery.
